Idorsia Ltd. has released its half-year financial report for 2025, highlighting significant advancements towards profitability. The company reported increased sales while materially lowering operational expenses. As of June 30, 2025, Idorsia's liquidity is expected to sustain operations until the end of 2026. The financial results reflect a US GAAP profitability driven by the Viatris deal. Idorsia continues to focus on unlocking the full value of QUVIVIQ, expanding strategic partnerships, and advancing its differentiated pipeline assets. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.